 In December 2013, New Zealand's government pharmaceutical buyer Pharmac declined a proposal to subsidize the drug after Alexion refused to budge on a NZ$670,000 (US$590,000) per person per year price and Pharmac's economic analysis determined the price would need to be halved before the drug was cost-effective enough to subsidize.Pharmac's decision upset many people with PNH in New Zealand PNH, although Pharmac has not ruled out reviewing the decision at a later date, should the drug be made available at a lower price.According to a 2014 report, the orphan drug market has become increasingly lucrative for a number of reasons.